Antiplatelet Therapy for AIS Patients With Thrombocytopenia (PERSIST)

Zhejiang University

Status

Enrolling

Conditions

Thrombocytopenia

Acute Ischemic Stroke

Treatments

Drug: aspirin, clopidogrel, cilostazol, and dipyridamole

Study type

Interventional

Funder types

Other

Identifiers

NCT06053021

PERSIST

Details and patient eligibility

About

The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Full description

Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.

Enrollment

1,200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age > 18 years old
Acute ischemic stroke or transient ischemic attack with onset < 7 days
The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9

Exclusion criteria

Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury
Indications for anticoagulation therapy, e.g. atrial fibrillation
Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
Have or plan to receive CEA or CAS in the following 3 months
Life expectancy less than 1 year
Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
Pregnant or lactating women
Individuals identified by researchers as unsuitable for participation in the study due to other reasons.